Halozyme Therapeutics Inc... (HALO)
NASDAQ: HALO
· Real-Time Price · USD
73.75
-0.22 (-0.30%)
At close: Sep 26, 2025, 3:59 PM
73.55
-0.27%
After-hours: Sep 26, 2025, 07:06 PM EDT
Halozyme Therapeutics Revenue Breakdown
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product Revenue | 179.3M | 154.2M | 144.13M | 86.66M | 84.3M | 72.7M | 79.6M | 86.57M | 73.89M | 1.71M | 14.35M | 48M | 20.73M | 25.53M | 12.32M | 32.22M | 60.32M | 30.33M | 57.25M | 32.34M | 33.04M | 385K | 13.74M | 416K | 15.28M | 17.95M | 6.38M | 2.4M | 571K | 3.38M |
Product Revenue Growth | +16.28% | +6.98% | +66.32% | +2.80% | +15.96% | -8.67% | -8.05% | +17.16% | +4223.52% | -88.09% | -70.09% | +131.59% | -18.83% | +107.32% | -61.78% | -46.58% | +98.85% | -47.02% | +77.04% | -2.12% | +8481.30% | -97.20% | +3203.37% | -97.28% | -14.88% | +181.44% | +165.57% | +320.67% | -83.10% | n/a |
Collaborative Agreements Revenue | 38.57M | 18.63M | 75.77M | 48.36M | 27.55M | 16.7M | 28.39M | 15.03M | 35.41M | 60.79M | 61.16M | 61.43M | 46.3M | 22.14M | 27.05M | 25.05M | 30.36M | 21.77M | 32.45M | 9.05M | 6.34M | 8.15M | 22.69M | 29.2M | 5.76M | 30.61M | n/a | n/a | n/a | n/a |
Collaborative Agreements Revenue Growth | +107.05% | -75.42% | +56.67% | +75.56% | +64.93% | -41.16% | +88.84% | -57.55% | -41.76% | -0.60% | -0.43% | +32.67% | +109.12% | -18.15% | +8.00% | -17.50% | +39.48% | -32.93% | +258.70% | +42.78% | -22.22% | -64.10% | -22.30% | +407.03% | -81.18% | n/a | n/a | n/a | n/a | n/a |
Royalty Revenue | 205.64M | 168.19M | 295.34M | 155.06M | 124.92M | 120.59M | 122.05M | 114.43M | 111.74M | 99.64M | 105.98M | 99.55M | 85.34M | 69.61M | 62.64M | 58.56M | 45.78M | 36.92M | 32M | 23.93M | 15.85M | 16.82M | 17.23M | 16.61M | 18.11M | 8.39M | n/a | n/a | n/a | n/a |
Royalty Revenue Growth | +22.26% | -43.05% | +90.47% | +24.13% | +3.59% | -1.20% | +6.66% | +2.41% | +12.14% | -5.98% | +6.46% | +16.65% | +22.61% | +11.13% | +6.95% | +27.93% | +23.98% | +15.40% | +33.71% | +51.02% | -5.80% | -2.37% | +3.74% | -8.27% | +115.82% | n/a | n/a | n/a | n/a | n/a |
Sales-based Milestone Revenue | 10M | 15M | n/a | 31.49M | 24.63M | 10.51M | n/a | 37M | 27.13M | 22.07M | 21.32M | 19.26M | 25.06M | 16.45M | 21.27M | 18.86M | 24.06M | 16.77M | 26.71M | 3.85M | 3.91M | 3.77M | 17.14M | 24.59M | 1.47M | 5.08M | n/a | n/a | n/a | n/a |
Sales-based Milestone Revenue Growth | -33.33% | n/a | n/a | +27.84% | +134.36% | n/a | n/a | +36.37% | +22.95% | +3.51% | +10.70% | -23.14% | +52.34% | -22.66% | +12.75% | -21.61% | +43.49% | -37.22% | +593.82% | -1.48% | +3.74% | -78.02% | -30.31% | +1572.99% | -71.07% | n/a | n/a | n/a | n/a | n/a |
bulk rHuPH20 Revenue | 23.27M | 27.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
bulk rHuPH20 Revenue Growth | -13.89% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 41.61M | 42.36M | 42.25M | 41.24M | 35.71M | 35.13M | 37.61M | 35.27M | 38.95M | 37.36M | 37.75M | 34.47M | 57.48M | 13.83M | 13.77M | 13.17M | 12.32M | 11.06M | 10.43M | 11.7M | 10.97M | 12.63M | 23.93M | 17.98M | 17.34M | 18.01M | 18.03M | 14.86M | 14.35M | 13.56M | 14.77M | 13.33M | 13.1M | 12.62M | 12.23M | 11.6M | 11.22M | 10.81M | 10.59M | 10.23M | 9.81M | 9.4M |
Selling, General, and Administrative Revenue Growth | -1.77% | +0.27% | +2.44% | +15.49% | +1.64% | -6.58% | +6.63% | -9.45% | +4.26% | -1.04% | +9.52% | -40.03% | +315.47% | +0.44% | +4.59% | +6.88% | +11.41% | +6.06% | -10.90% | +6.62% | -13.12% | -47.21% | +33.09% | +3.70% | -3.71% | -0.14% | +21.31% | +3.56% | +5.88% | -8.23% | +10.82% | +1.74% | +3.85% | +3.17% | +5.41% | +3.37% | +3.84% | +2.05% | +3.55% | +4.20% | +4.42% | n/a |
Research and Development Revenue | 17.54M | 14.8M | 20.44M | 18.46M | 21.04M | 19.11M | 21.34M | 17.32M | 19.73M | 17.98M | 22.57M | 16.7M | 15.48M | 11.85M | 10.11M | 8.49M | 8.07M | 9.01M | 7.38M | 7.75M | 8.95M | 10.16M | 45.11M | 30.45M | 33.91M | 31.33M | 36.65M | 35.54M | 40.09M | 37.98M | 41.38M | 33.99M | 38.34M | 36.94M | 41.35M | 33.86M | 35.53M | 40.1M | 27.75M | 27.61M | 21.2M | 16.68M |
Research and Development Revenue Growth | +18.54% | -27.60% | +10.74% | -12.26% | +10.08% | -10.43% | +23.18% | -12.20% | +9.72% | -20.33% | +35.09% | +7.89% | +30.63% | +17.26% | +19.11% | +5.17% | -10.43% | +22.07% | -4.74% | -13.45% | -11.88% | -77.48% | +48.12% | -10.19% | +8.24% | -14.52% | +3.12% | -11.34% | +5.56% | -8.22% | +21.72% | -11.34% | +3.80% | -10.67% | +22.11% | -4.69% | -11.40% | +44.53% | +0.49% | +30.27% | +27.04% | n/a |